Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3018829 | 0.81 | MEN1 (0.53) | GAAKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL31527868 | 0.71 | GAA (0.73) | LMNAMCL1GAAKMT2AMEN1 | |
| SCHEMBL1791238 | 0.71 | GAA (0.73) | LMNAMCL1GAAKMT2AMEN1 | |
| SCHEMBL11521594 | 0.70 | MAPK10 (0.62) | GAAKMT2AMEN1HTTALDH1A1 | |
| SCHEMBL16666142 | 0.69 | GLA (0.52) | LMNAMCL1GAAKMT2AMEN1 | |
| SCHEMBL11453402 | 0.68 | GPR35 (0.58) | LMNAMCL1GAAKMT2AALDH1A1 | |
| SCHEMBL7165819 | 0.68 | MAPT (0.63) | LMNAGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL2835288 | 0.68 | GAA (0.73) | LMNAMCL1GAAKMT2AMEN1 | |
| SCHEMBL29612239 | 0.67 | GAA (0.67) | LMNAMCL1GAAKMT2AMEN1 | |
| SCHEMBL744526 | 0.67 | GAA (0.67) | LMNAMCL1GAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741483-B2 | Process for making substituted pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of phosphodiesterase 5 | YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2010-06-22 | — | — | US | disclosed |
| US-20080167462-A1 | 2-substituted phenyl-5, 7-dehydrocarbyl-3, 7-dihydropyrrolo [2, 3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | TIANJIN TASLY GROUP CO., LTD (CN) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167462-A1 | 2-substituted phenyl-5, 7-dehydrocarbyl-3, 7-dihydropyrrolo [2, 3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | PDE5A, PDE3B, PDE2A | LMNA 2581/4885MCL1 4824/4885GAA 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.